Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $54.55 million. The enterprise value is $34.22 million.

Market Cap	54.55M
Enterprise Value	34.22M

Important Dates

The next estimated earnings date is Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Cue Biopharma has 76.85 million shares outstanding. The number of shares has increased by 52.88% in one year.

Current Share Class	76.85M
Shares Outstanding	76.85M
Shares Change (YoY)	+52.88%
Shares Change (QoQ)	+28.56%
Owned by Insiders (%)	0.35%
Owned by Institutions (%)	24.02%
Float	76.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.33
Forward PS	5.77
PB Ratio	2.99
P/TBV Ratio	3.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.42.

Current Ratio	1.60
Quick Ratio	1.48
Debt / Equity	0.42
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-77.10

Financial Efficiency

Return on equity (ROE) is -195.55% and return on invested capital (ROIC) is -84.10%.

Return on Equity (ROE)	-195.55%
Return on Assets (ROA)	-59.43%
Return on Invested Capital (ROIC)	-84.10%
Return on Capital Employed (ROCE)	-184.02%
Revenue Per Employee	$202,098
Profits Per Employee	-$948,659
Employee Count	41
Asset Turnover	0.20
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +49.40% in the last 52 weeks. The beta is 1.59, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.59
52-Week Price Change	+49.40%
50-Day Moving Average	0.79
200-Day Moving Average	0.92
Relative Strength Index (RSI)	41.00
Average Volume (20 Days)	130,667

Short Selling Information

The latest short interest is 665,931, so 0.87% of the outstanding shares have been sold short.

Short Interest	665,931
Short Previous Month	898,157
Short % of Shares Out	0.87%
Short % of Float	0.87%
Short Ratio (days to cover)	5.06

Income Statement

In the last 12 months, Cue Biopharma had revenue of $8.29 million and -$38.90 million in losses. Loss per share was -$0.53.

Revenue	8.29M
Gross Profit	-24.74M
Operating Income	-39.48M
Pretax Income	-38.90M
Net Income	-38.90M
EBITDA	-39.08M
EBIT	-39.48M
Loss Per Share	-$0.53

Full Income Statement

Balance Sheet

The company has $27.96 million in cash and $7.63 million in debt, giving a net cash position of $20.33 million or $0.26 per share.

Cash & Cash Equivalents	27.96M
Total Debt	7.63M
Net Cash	20.33M
Net Cash Per Share	$0.26
Equity (Book Value)	18.16M
Book Value Per Share	0.24
Working Capital	11.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$28.14 million and capital expenditures -$178,000, giving a free cash flow of -$28.32 million.

Operating Cash Flow	-28.14M
Capital Expenditures	-178,000
Free Cash Flow	-28.32M
FCF Per Share	-$0.37

Full Cash Flow Statement

Margins

Gross Margin	-298.54%
Operating Margin	-476.43%
Pretax Margin	-469.41%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.88%
Shareholder Yield	-52.88%
Earnings Yield	-71.31%
FCF Yield	-51.92%

Analyst Forecast

The average price target for Cue Biopharma is $3.00, which is 322.65% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	322.65%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	75.28%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cue Biopharma has an Altman Z-Score of -13.52 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.52
Piotroski F-Score	3